Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Current Assets for the year ending December 31, 2023: USD 179.89 M

Allakos Inc Current Assets is USD 179.89 M for the year ending December 31, 2023, a -41.75% change year over year. Current Assets are assets that are expected to be converted into cash or used within one year.

Allakos Inc Current Assets for the year ending December 31, 2022 was USD 308.84 M, a -31.61% change year over year.
Allakos Inc Current Assets for the year ending December 31, 2021 was USD 451.58 M, a -32.53% change year over year.
Allakos Inc Current Assets for the year ending December 31, 2020 was USD 669.27 M, a 33.89% change year over year.
Allakos Inc Current Assets for the year ending December 31, 2019 was USD 499.87 M, a 175.25% change year over year.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends